Study Details
Testing the Drug Dexpramipexole in People with Eosinophilic Asthma
(IRB#: IRB_00178852)
Eosinophilic asthma is a condition when there is a high level of white blood cells and a persons airway becomes narrow and swollen making it difficult to breathe. This study will test a drug called Dexpramipexole (Dex) to treat adults with severe eosinophilic asthma. This study wants to see if Dex added to current medications will help people with the condition and is safe. People in the study will be randomly chosen to be in one of three study groups. Two of the groups will receive different doses of the study drug. One group will receive the placebo. The placebo looks like the study drug but does not have the medication. Being in the study requires attending 11 visits over 56 weeks. Ten of the visits will be in person at the study clinic. Each visit lasts about 1 to 3 hours. The last visit will be a telephone call that will last about 30 minutes. Medical tests will be done during the study to track the health of participants.
- All genders
- Over 7 years old
- Volunteers with special conditions
- In Person
- Paid
Who can participate?
Gender: All genders
Age: Over 7 years old
Volunteers: Volunteers with special conditions
Location: In Person
Inclusion Criteria
- Ages 12 years and older
- Diagnosed with Asthma for at least 1 year
- History of at least 2 asthma attacks requiring treatment with specific medication within the past 12 months
- Able to attend in-person visits at the study clinic
Exclusion Criteria
- Severe asthma attack that requires emergency treatment any time from 4 weeks before participation
- Diagnosis of diseases that impact full participation
- Respiratory infection such as pneumonia 4 weeks before participation
- Current smoking within 12 months before participation
- Pregnant
Will I be paid for my time?
Yes
IRB#: IRB_00178852
PI: Mili Shum
Department: DERMATOLOGY
Approval Date: 2024-10-16 06:00:00
Specialties: Dermatology
I am Interested